JP2016511258A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016511258A5 JP2016511258A5 JP2015560325A JP2015560325A JP2016511258A5 JP 2016511258 A5 JP2016511258 A5 JP 2016511258A5 JP 2015560325 A JP2015560325 A JP 2015560325A JP 2015560325 A JP2015560325 A JP 2015560325A JP 2016511258 A5 JP2016511258 A5 JP 2016511258A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- amino
- independently
- oxazin
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 CH 2 OH Chemical group 0.000 claims 109
- 125000000217 alkyl group Chemical group 0.000 claims 59
- 150000001875 compounds Chemical class 0.000 claims 42
- 229910052731 fluorine Inorganic materials 0.000 claims 37
- 229910052799 carbon Inorganic materials 0.000 claims 32
- 150000003839 salts Chemical class 0.000 claims 31
- 229910052739 hydrogen Inorganic materials 0.000 claims 30
- 125000003342 alkenyl group Chemical group 0.000 claims 29
- 125000004432 carbon atom Chemical group C* 0.000 claims 28
- 229910052757 nitrogen Inorganic materials 0.000 claims 28
- 125000000304 alkynyl group Chemical group 0.000 claims 27
- 125000005842 heteroatom Chemical group 0.000 claims 27
- 229910052760 oxygen Inorganic materials 0.000 claims 24
- 229910052801 chlorine Inorganic materials 0.000 claims 23
- 125000005309 thioalkoxy group Chemical group 0.000 claims 21
- 125000001153 fluoro group Chemical group F* 0.000 claims 20
- 125000001424 substituent group Chemical group 0.000 claims 20
- 125000004663 dialkyl amino group Chemical group 0.000 claims 19
- 125000003545 alkoxy group Chemical group 0.000 claims 14
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 claims 14
- 125000002757 morpholinyl group Chemical group 0.000 claims 14
- 125000003226 pyrazolyl group Chemical group 0.000 claims 14
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 13
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 12
- 125000003282 alkyl amino group Chemical group 0.000 claims 12
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 12
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 11
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 11
- 125000000842 isoxazolyl group Chemical group 0.000 claims 11
- 125000001188 haloalkyl group Chemical group 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
- QMYGFTJCQFEDST-UHFFFAOYSA-N 3-methoxybutyl acetate Chemical group COC(C)CCOC(C)=O QMYGFTJCQFEDST-UHFFFAOYSA-N 0.000 claims 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 7
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 7
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 7
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 7
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 7
- 125000000168 pyrrolyl group Chemical group 0.000 claims 7
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 206010012289 Dementia Diseases 0.000 claims 4
- 125000002619 bicyclic group Chemical group 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 229940125810 compound 20 Drugs 0.000 claims 2
- 229940126086 compound 21 Drugs 0.000 claims 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- IDHAZTOESFWNSY-WMLDXEAASA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-chloropyridine-2-carboxamide Chemical compound C1[C@@H](C(F)(F)F)OC(N)=N[C@]1(CF)C1=CC(NC(=O)C=2N=CC(Cl)=CC=2)=CC=C1F IDHAZTOESFWNSY-WMLDXEAASA-N 0.000 claims 2
- LUIXXFPAAMIKOX-LRDDRELGSA-N n-[5-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-6-fluoropyridin-3-yl]-5-chloropyridine-2-carboxamide Chemical compound C=1C(NC(=O)C=2N=CC(Cl)=CC=2)=CN=C(F)C=1[C@]1(C)C[C@@H](C(F)(F)F)OC(N)=N1 LUIXXFPAAMIKOX-LRDDRELGSA-N 0.000 claims 2
- GZQHKBFOERBNAG-GUYCJALGSA-N n-[5-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-6-fluoropyridin-3-yl]-5-cyanopyridine-2-carboxamide Chemical compound C=1C(NC(=O)C=2N=CC(=CC=2)C#N)=CN=C(F)C=1[C@]1(C)C[C@@H](C(F)(F)F)OC(N)=N1 GZQHKBFOERBNAG-GUYCJALGSA-N 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- PCNDBEIQPLJGIC-KUHUBIRLSA-N (4r,6r)-4-[2-fluoro-5-[(2-methoxypyrido[3,4-b]pyrazin-5-yl)amino]phenyl]-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-2-amine Chemical compound N=1C=CC2=NC(OC)=CN=C2C=1NC(C=1)=CC=C(F)C=1[C@@]1(CF)C[C@H](C(F)(F)F)OC(N)=N1 PCNDBEIQPLJGIC-KUHUBIRLSA-N 0.000 claims 1
- CCHOGVQCNCTVED-HNAYVOBHSA-N (4s,6s)-4-[5-[(3-chloro-1,7-naphthyridin-8-yl)amino]-2-fluorophenyl]-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-2-amine Chemical compound C1[C@@H](C(F)(F)F)OC(N)=N[C@]1(CF)C1=CC(NC=2C3=NC=C(Cl)C=C3C=CN=2)=CC=C1F CCHOGVQCNCTVED-HNAYVOBHSA-N 0.000 claims 1
- GDGGLXWHVCHUOD-SJCJKPOMSA-N (4s,6s)-4-[5-[(7-chloropyrido[3,2-d]pyrimidin-4-yl)amino]-2-fluoropyridin-3-yl]-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-2-amine Chemical compound C=1C(NC=2C3=NC=C(Cl)C=C3N=CN=2)=CN=C(F)C=1[C@]1(C)C[C@@H](C(F)(F)F)OC(N)=N1 GDGGLXWHVCHUOD-SJCJKPOMSA-N 0.000 claims 1
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N 2,3-dimethylpyridine Chemical compound CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 claims 1
- KJBKHJJJGKNGTR-UGSOOPFHSA-N 4-[[5-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-6-fluoropyridin-3-yl]amino]pyrido[3,2-d]pyrimidine-7-carbonitrile Chemical compound C=1C(NC=2C3=NC=C(C=C3N=CN=2)C#N)=CN=C(F)C=1[C@]1(C)C[C@@H](C(F)(F)F)OC(N)=N1 KJBKHJJJGKNGTR-UGSOOPFHSA-N 0.000 claims 1
- QJQLEDGUNULCGG-OXJNMPFZSA-N 8-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluoroanilino]-1,7-naphthyridine-3-carbonitrile Chemical compound C1[C@@H](C(F)(F)F)OC(N)=N[C@]1(CF)C1=CC(NC=2C3=NC=C(C=C3C=CN=2)C#N)=CC=C1F QJQLEDGUNULCGG-OXJNMPFZSA-N 0.000 claims 1
- LWXHQLQQXIEDPY-OXJNMPFZSA-N 8-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluoroanilino]-5-fluoro-1,7-naphthyridine-3-carbonitrile Chemical compound C1[C@@H](C(F)(F)F)OC(N)=N[C@]1(CF)C1=CC(NC=2C3=NC=C(C=C3C(F)=CN=2)C#N)=CC=C1F LWXHQLQQXIEDPY-OXJNMPFZSA-N 0.000 claims 1
- VFSFJNSLXGLHOI-LIRRHRJNSA-N 8-[[5-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-6-fluoropyridin-3-yl]amino]-1,7-naphthyridine-3-carbonitrile Chemical compound C=1C(NC=2C3=NC=C(C=C3C=CN=2)C#N)=CN=C(F)C=1[C@]1(C)C[C@@H](C(F)(F)F)OC(N)=N1 VFSFJNSLXGLHOI-LIRRHRJNSA-N 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000004558 lewy body Anatomy 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- BLNHQDSKCVQIOQ-GUYCJALGSA-N n-[3-[(4r,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-methoxypyrazine-2-carboxamide Chemical compound C1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@]2(CF)N=C(N)O[C@@H](C2)C(F)(F)F)=C1 BLNHQDSKCVQIOQ-GUYCJALGSA-N 0.000 claims 1
- SXGOGHFRCNZQNM-SUMWQHHRSA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-3,5-dichloropyridine-2-carboxamide Chemical compound C1[C@@H](C(F)(F)F)OC(N)=N[C@]1(CF)C1=CC(NC(=O)C=2C(=CC(Cl)=CN=2)Cl)=CC=C1F SXGOGHFRCNZQNM-SUMWQHHRSA-N 0.000 claims 1
- MOMLEQNWBDCETG-KBXCAEBGSA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-3-chloro-5-cyanopyridine-2-carboxamide Chemical compound C1[C@@H](C(F)(F)F)OC(N)=N[C@]1(CF)C1=CC(NC(=O)C=2C(=CC(=CN=2)C#N)Cl)=CC=C1F MOMLEQNWBDCETG-KBXCAEBGSA-N 0.000 claims 1
- DDSHXFILKTVOHT-KBXCAEBGSA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-3-chloro-5-methoxypyridine-2-carboxamide Chemical compound ClC1=CC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]2(CF)N=C(N)O[C@@H](C2)C(F)(F)F)=C1 DDSHXFILKTVOHT-KBXCAEBGSA-N 0.000 claims 1
- VBRNPACCSYLXRZ-MGPUTAFESA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-3-methylimidazo[1,2-a]pyridine-2-carboxamide Chemical compound N1=C2C=CC=CN2C(C)=C1C(=O)NC(C=1)=CC=C(F)C=1[C@]1(CF)C[C@@H](C(F)(F)F)OC(N)=N1 VBRNPACCSYLXRZ-MGPUTAFESA-N 0.000 claims 1
- GXYRXKLMYVNONT-MAUKXSAKSA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-(2,2,2-trifluoroethoxy)pyridine-2-carboxamide Chemical compound C1[C@@H](C(F)(F)F)OC(N)=N[C@]1(CF)C1=CC(NC(=O)C=2N=CC(OCC(F)(F)F)=CC=2)=CC=C1F GXYRXKLMYVNONT-MAUKXSAKSA-N 0.000 claims 1
- BWKHCKWUYYLDFL-SUMWQHHRSA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-bromo-3-chloropyridine-2-carboxamide Chemical compound C1[C@@H](C(F)(F)F)OC(N)=N[C@]1(CF)C1=CC(NC(=O)C=2C(=CC(Br)=CN=2)Cl)=CC=C1F BWKHCKWUYYLDFL-SUMWQHHRSA-N 0.000 claims 1
- QKABRHMRLFQOCY-WMLDXEAASA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-bromopyridine-2-carboxamide Chemical compound C1[C@@H](C(F)(F)F)OC(N)=N[C@]1(CF)C1=CC(NC(=O)C=2N=CC(Br)=CC=2)=CC=C1F QKABRHMRLFQOCY-WMLDXEAASA-N 0.000 claims 1
- OJXHVKRDKPVNQU-KBXCAEBGSA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-chloro-3-methoxypyridine-2-carboxamide Chemical compound COC1=CC(Cl)=CN=C1C(=O)NC1=CC=C(F)C([C@@]2(CF)N=C(N)O[C@@H](C2)C(F)(F)F)=C1 OJXHVKRDKPVNQU-KBXCAEBGSA-N 0.000 claims 1
- GSHVOYWQLKOCLX-KBXCAEBGSA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-chloro-3-methylpyridine-2-carboxamide Chemical compound CC1=CC(Cl)=CN=C1C(=O)NC1=CC=C(F)C([C@@]2(CF)N=C(N)O[C@@H](C2)C(F)(F)F)=C1 GSHVOYWQLKOCLX-KBXCAEBGSA-N 0.000 claims 1
- CBFVEIDAVVTRFQ-HNAYVOBHSA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-cyano-3-methylpyridine-2-carboxamide Chemical compound CC1=CC(C#N)=CN=C1C(=O)NC1=CC=C(F)C([C@@]2(CF)N=C(N)O[C@@H](C2)C(F)(F)F)=C1 CBFVEIDAVVTRFQ-HNAYVOBHSA-N 0.000 claims 1
- QCMXWFUAVCHHIA-MAUKXSAKSA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-cyanopyridine-2-carboxamide Chemical compound C1[C@@H](C(F)(F)F)OC(N)=N[C@]1(CF)C1=CC(NC(=O)C=2N=CC(=CC=2)C#N)=CC=C1F QCMXWFUAVCHHIA-MAUKXSAKSA-N 0.000 claims 1
- NJIHNSPWTBSFKB-WMLDXEAASA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxamide Chemical compound C1[C@@H](C(F)(F)F)OC(N)=N[C@]1(CF)C1=CC(NC(=O)C=2N=CC(F)=CC=2)=CC=C1F NJIHNSPWTBSFKB-WMLDXEAASA-N 0.000 claims 1
- FOWQPYBFNSIGLL-SCLBCKFNSA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-methoxy-3-methylpyrazine-2-carboxamide Chemical compound CC1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]2(CF)N=C(N)O[C@@H](C2)C(F)(F)F)=C1 FOWQPYBFNSIGLL-SCLBCKFNSA-N 0.000 claims 1
- BLNHQDSKCVQIOQ-SUMWQHHRSA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-methoxypyrazine-2-carboxamide Chemical compound C1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]2(CF)N=C(N)O[C@@H](C2)C(F)(F)F)=C1 BLNHQDSKCVQIOQ-SUMWQHHRSA-N 0.000 claims 1
- HHBMLXDPSJOPLK-MAUKXSAKSA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-methoxypyridine-2-carboxamide Chemical compound N1=CC(OC)=CC=C1C(=O)NC1=CC=C(F)C([C@@]2(CF)N=C(N)O[C@@H](C2)C(F)(F)F)=C1 HHBMLXDPSJOPLK-MAUKXSAKSA-N 0.000 claims 1
- HCDBRYXKOZVMHM-MGPUTAFESA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-6-chloro-3-methylimidazo[1,2-a]pyridine-2-carboxamide Chemical compound N1=C2C=CC(Cl)=CN2C(C)=C1C(=O)NC(C=1)=CC=C(F)C=1[C@]1(CF)C[C@@H](C(F)(F)F)OC(N)=N1 HCDBRYXKOZVMHM-MGPUTAFESA-N 0.000 claims 1
- FLOQLFHUIOTUTO-KSSFIOAISA-N n-[3-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-chloro-3-methylpyridine-2-carboxamide Chemical compound CC1=CC(Cl)=CN=C1C(=O)NC1=CC=C(F)C([C@@]2(C)N=C(N)O[C@@H](C2)C(F)(F)F)=C1 FLOQLFHUIOTUTO-KSSFIOAISA-N 0.000 claims 1
- GLPZXCBSTJTISQ-YOEHRIQHSA-N n-[3-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-chloropyridine-2-carboxamide Chemical compound C=1C(NC(=O)C=2N=CC(Cl)=CC=2)=CC=C(F)C=1[C@]1(C)C[C@@H](C(F)(F)F)OC(N)=N1 GLPZXCBSTJTISQ-YOEHRIQHSA-N 0.000 claims 1
- MELQHVBGGSKVJQ-YJBOKZPZSA-N n-[3-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-cyanopyridine-2-carboxamide Chemical compound C=1C(NC(=O)C=2N=CC(=CC=2)C#N)=CC=C(F)C=1[C@]1(C)C[C@@H](C(F)(F)F)OC(N)=N1 MELQHVBGGSKVJQ-YJBOKZPZSA-N 0.000 claims 1
- XQAPROTXNTWGLK-GUYCJALGSA-N n-[3-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-methoxypyrazine-2-carboxamide Chemical compound C1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]2(C)N=C(N)O[C@@H](C2)C(F)(F)F)=C1 XQAPROTXNTWGLK-GUYCJALGSA-N 0.000 claims 1
- WTQJLKGKDKGXBB-ZBEGNZNMSA-N n-[5-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-6-fluoropyridin-3-yl]-3,5-dichloropyridine-2-carboxamide Chemical compound C=1C(NC(=O)C=2C(=CC(Cl)=CN=2)Cl)=CN=C(F)C=1[C@]1(C)C[C@@H](C(F)(F)F)OC(N)=N1 WTQJLKGKDKGXBB-ZBEGNZNMSA-N 0.000 claims 1
- QDBLNVMBHVAXAF-SJCJKPOMSA-N n-[5-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-6-fluoropyridin-3-yl]-3-chloro-5-methoxypyridine-2-carboxamide Chemical compound ClC1=CC(OC)=CN=C1C(=O)NC1=CN=C(F)C([C@@]2(C)N=C(N)O[C@@H](C2)C(F)(F)F)=C1 QDBLNVMBHVAXAF-SJCJKPOMSA-N 0.000 claims 1
- OYOWKRLQEBXXFF-SJCJKPOMSA-N n-[5-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-6-fluoropyridin-3-yl]-5-chloro-3-methylpyridine-2-carboxamide Chemical compound CC1=CC(Cl)=CN=C1C(=O)NC1=CN=C(F)C([C@@]2(C)N=C(N)O[C@@H](C2)C(F)(F)F)=C1 OYOWKRLQEBXXFF-SJCJKPOMSA-N 0.000 claims 1
- AOLLQRLVRFPHMU-UGSOOPFHSA-N n-[5-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-6-fluoropyridin-3-yl]-5-cyano-3-methylpyridine-2-carboxamide Chemical compound CC1=CC(C#N)=CN=C1C(=O)NC1=CN=C(F)C([C@@]2(C)N=C(N)O[C@@H](C2)C(F)(F)F)=C1 AOLLQRLVRFPHMU-UGSOOPFHSA-N 0.000 claims 1
- RPUXRRILZNMEFF-QFYYESIMSA-N n-[6-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-5-fluoropyridin-2-yl]-3,5-dichloropyridine-2-carboxamide Chemical compound N=1C(NC(=O)C=2C(=CC(Cl)=CN=2)Cl)=CC=C(F)C=1[C@]1(C)C[C@@H](C(F)(F)F)OC(N)=N1 RPUXRRILZNMEFF-QFYYESIMSA-N 0.000 claims 1
- XUSLPMBGYMTYIP-QFYYESIMSA-N n-[6-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-5-fluoropyridin-2-yl]-3-chloro-5-(trifluoromethyl)pyridine-2-carboxamide Chemical compound N=1C(NC(=O)C=2C(=CC(=CN=2)C(F)(F)F)Cl)=CC=C(F)C=1[C@]1(C)C[C@@H](C(F)(F)F)OC(N)=N1 XUSLPMBGYMTYIP-QFYYESIMSA-N 0.000 claims 1
- SEDNJKRDPITJTN-GTNSWQLSSA-N n-[6-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-5-fluoropyridin-2-yl]-3-chloro-5-cyanopyridine-2-carboxamide Chemical compound N=1C(NC(=O)C=2C(=CC(=CN=2)C#N)Cl)=CC=C(F)C=1[C@]1(C)C[C@@H](C(F)(F)F)OC(N)=N1 SEDNJKRDPITJTN-GTNSWQLSSA-N 0.000 claims 1
- FWHRMLYVMNQBGS-ZBEGNZNMSA-N n-[6-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-5-fluoropyridin-2-yl]-5-chloropyridine-2-carboxamide Chemical compound N=1C(NC(=O)C=2N=CC(Cl)=CC=2)=CC=C(F)C=1[C@]1(C)C[C@@H](C(F)(F)F)OC(N)=N1 FWHRMLYVMNQBGS-ZBEGNZNMSA-N 0.000 claims 1
- JDFWETJUGPKDKZ-SJCJKPOMSA-N n-[6-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-5-fluoropyridin-2-yl]-5-cyanopyridine-2-carboxamide Chemical compound N=1C(NC(=O)C=2N=CC(=CC=2)C#N)=CC=C(F)C=1[C@]1(C)C[C@@H](C(F)(F)F)OC(N)=N1 JDFWETJUGPKDKZ-SJCJKPOMSA-N 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 230000007505 plaque formation Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229960005206 pyrazinamide Drugs 0.000 claims 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 claims 1
- 0 C*C(C1(*)N=C(N)OC(C(F)(F)F)C1(*)*)=*C(*)=*[*-] Chemical compound C*C(C1(*)N=C(N)OC(C(F)(F)F)C1(*)*)=*C(*)=*[*-] 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361771615P | 2013-03-01 | 2013-03-01 | |
| US61/771,615 | 2013-03-01 | ||
| US201361826431P | 2013-05-22 | 2013-05-22 | |
| US61/826,431 | 2013-05-22 | ||
| US201461928898P | 2014-01-17 | 2014-01-17 | |
| US61/928,898 | 2014-01-17 | ||
| PCT/US2014/019100 WO2014134341A1 (en) | 2013-03-01 | 2014-02-27 | Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016511258A JP2016511258A (ja) | 2016-04-14 |
| JP2016511258A5 true JP2016511258A5 (cg-RX-API-DMAC7.html) | 2017-03-30 |
| JP6389830B2 JP6389830B2 (ja) | 2018-09-12 |
Family
ID=50349866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560325A Active JP6389830B2 (ja) | 2013-03-01 | 2014-02-27 | ベータ−セクレターゼ阻害剤としてのパーフルオロ化５，６−ジヒドロ−４ｈ−１，３−オキサジン−２−アミン化合物および使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9296734B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2961749B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6389830B2 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2014223334C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2902212C (cg-RX-API-DMAC7.html) |
| MX (1) | MX366855B (cg-RX-API-DMAC7.html) |
| TW (1) | TW201446758A (cg-RX-API-DMAC7.html) |
| UY (1) | UY35361A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014134341A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009258496B8 (en) | 2008-06-13 | 2014-06-26 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity |
| US8999980B2 (en) † | 2009-12-11 | 2015-04-07 | Shionogi & Co., Ltd. | Oxazine derivatives |
| EP2912035A4 (en) | 2012-10-24 | 2016-06-15 | Shionogi & Co | DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY |
| TW201446758A (zh) | 2013-03-01 | 2014-12-16 | Amgen Inc | 作爲β－分泌酶抑制劑的全氟化５，６－二氫－４Ｈ－１，３－□－２－胺化合物及其用途 |
| HK1217486A1 (zh) | 2013-03-08 | 2017-01-13 | Amgen Inc. | 作爲β-分泌酶抑制剂的全氟化环丙基稠合的1，3-恶嗪-2-胺化合物以及其使用方法 |
| MA38556A1 (fr) | 2013-04-11 | 2017-09-29 | Hoffmann La Roche | Inhibiteurs de bace1 |
| PE20161225A1 (es) | 2014-02-19 | 2016-12-04 | H Lundbeck As | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer |
| TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物 |
| AU2015301028B2 (en) | 2014-08-08 | 2019-09-26 | Amgen Inc. | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
| JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
| MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
| TW201717948A (zh) | 2015-08-10 | 2017-06-01 | Ｈ 朗德貝克公司 | 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療 |
| AR105668A1 (es) | 2015-08-12 | 2017-10-25 | H Lundbeck As | 2-amino-3-fluoro-3-(fluorometil)-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 |
| TW201726651A (zh) | 2015-09-23 | 2017-08-01 | 健生藥品公司 | ２，３，４，５－四氫吡啶－６－胺衍生物 |
| WO2017061534A1 (en) | 2015-10-08 | 2017-04-13 | Shionogi & Co., Ltd. | Dihydrothiazine derivatives |
| CN108430982A (zh) | 2015-12-25 | 2018-08-21 | 盐野义制药株式会社 | 用于制备噻嗪衍生物的方法和中间体 |
| JP6616525B2 (ja) * | 2016-03-01 | 2019-12-04 | エフ．ホフマン−ラ ロシュ アーゲー | Ｂａｃｅ１阻害剤 |
| AU2017378316B2 (en) * | 2016-12-15 | 2021-04-01 | Amgen Inc. | Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use |
| MY199348A (en) * | 2017-04-27 | 2023-10-24 | Basf Se | Process for preparing optically active 2,3-dihydrothiazolo[3,2-a]pyrimidin-4-ium compounds |
| KR20210003872A (ko) | 2018-04-27 | 2021-01-12 | 시오노기 앤드 컴파니, 리미티드 | 선택적 bace1 억제 활성을 갖는 테트라하이드로피라노옥사진 유도체 |
| TWI797167B (zh) * | 2018-09-28 | 2023-04-01 | 德商巴地斯顏料化工廠 | 用於製備光學活性嘧啶鎓化合物之方法 |
| TWI780230B (zh) * | 2018-09-28 | 2022-10-11 | 德商巴地斯顏料化工廠 | 用於製備含硫之嘧啶鎓化合物之方法 |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Ａｌｋ﹘５抑制劑和彼之用途 |
| CN113979993B (zh) * | 2021-11-29 | 2023-10-13 | 云南萃精生物科技有限责任公司 | 一种不对称合成（s）-烟碱的方法 |
| CN114561435B (zh) * | 2022-04-27 | 2022-08-30 | 南京科力硕生物科技有限公司 | 利用磁性碳纳米管固定化酶催化制备4-氯-3-乙基-1-甲基吡唑-5-甲酸的方法 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5441870A (en) | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
| SI9300303A (en) | 1993-06-08 | 1994-12-31 | Krka Tovarna Zdravil | Process for isolation of hypolipemic effective substance |
| EP0871720A2 (en) | 1995-06-07 | 1998-10-21 | Athena Neurosciences, Inc. | Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition |
| EP1115874B1 (en) | 1998-09-24 | 2009-01-07 | Pharmacia & Upjohn Company LLC | Alzheimer's disease secretase |
| US20040234976A1 (en) | 1998-09-24 | 2004-11-25 | Gurney Mark E. | Alzheimer's disease secretase, app substrates therefor, and uses therefor |
| CN102627609B (zh) | 2003-12-15 | 2016-05-04 | 默沙东公司 | 杂环天冬氨酰蛋白酶抑制剂 |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| KR101052122B1 (ko) | 2005-10-25 | 2011-07-26 | 시오노기세야쿠 가부시키가이샤 | 아미노디히드로티아진 유도체 |
| MX2009011498A (es) | 2007-04-24 | 2009-11-10 | Shionogi & Co | Derivados de aminodihidrotiazina sustituida con un grupo ciclico. |
| WO2008133273A1 (ja) | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | アルツハイマー症治療用医薬組成物 |
| US7897619B2 (en) | 2007-07-17 | 2011-03-01 | Amgen Inc. | Heterocyclic modulators of PKB |
| KR20100038119A (ko) | 2007-08-01 | 2010-04-12 | 화이자 인코포레이티드 | 피라졸 화합물 및 ｒａｆ 억제제로서 이의 용도 |
| US20100317850A1 (en) | 2008-01-18 | 2010-12-16 | Yuichi Suzuki | Condensed aminodihydrothiazine derivative |
| TWI431004B (zh) | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Ｂａｃｅ抑制劑 |
| AU2009258496B8 (en) | 2008-06-13 | 2014-06-26 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity |
| AU2009277485B2 (en) | 2008-07-28 | 2013-05-02 | Eisai R&D Management Co., Ltd. | Spiroaminodihydrothiazine derivatives |
| WO2010013302A1 (ja) | 2008-07-28 | 2010-02-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スピロアミノジヒドロチアジン誘導体 |
| US8461160B2 (en) | 2009-05-08 | 2013-06-11 | Hoffmann-La Roche, Inc. | Dihydropyrimidinones |
| AR077277A1 (es) * | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
| GB0912778D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
| US8188079B2 (en) | 2009-08-19 | 2012-05-29 | Hoffman-La Roche Inc. | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines |
| US20110065695A1 (en) | 2009-09-11 | 2011-03-17 | Jeremy Beauchamp | Use of aminodihydrothiazines for the treatment or prevention of diabetes |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| US20120238557A1 (en) | 2009-11-13 | 2012-09-20 | Shionogi & Co., Ltd. | Aminothiazine or aminooxazine derivative having amino linker |
| WO2011070781A1 (ja) | 2009-12-09 | 2011-06-16 | 塩野義製薬株式会社 | 置換アミノチアジン誘導体 |
| WO2011071057A1 (ja) * | 2009-12-09 | 2011-06-16 | 塩野義製薬株式会社 | 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物 |
| US7964594B1 (en) | 2009-12-10 | 2011-06-21 | Hoffmann-La Roche Inc. | Amino oxazine derivatives |
| EP2511269A4 (en) | 2009-12-11 | 2013-04-24 | Shionogi & Co | FUSED HETEROCYCLIC COMPOUND HAVING AN AMINO GROUP |
| US8999980B2 (en) | 2009-12-11 | 2015-04-07 | Shionogi & Co., Ltd. | Oxazine derivatives |
| UA103272C2 (uk) * | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
| WO2012078994A1 (en) | 2010-12-09 | 2012-06-14 | Janssen Pharmaceutica Nv | Imidazo [1, 2-a] pyridine sulfonamides as trpm8 modulators |
| EA201391029A1 (ru) | 2011-01-12 | 2014-01-30 | Новартис Аг | Производные оксазина и их применение при лечении неврологических нарушений |
| MX2013008192A (es) | 2011-01-13 | 2013-12-16 | Novartis Ag | Inhibidores de bace-2 para tratamiento de transtornos metabolicos. |
| KR101569260B1 (ko) | 2011-01-13 | 2015-11-13 | 노파르티스 아게 | 신규 헤테로시클릭 유도체 및 신경계 장애의 치료에서의 그의 용도 |
| US8404680B2 (en) | 2011-02-08 | 2013-03-26 | Hoffmann-La Roche Inc. | N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors |
| US9221839B2 (en) | 2011-04-07 | 2015-12-29 | Merck Sharp & Dohme Corp. | C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
| US8754075B2 (en) | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
| US9499502B2 (en) | 2011-04-13 | 2016-11-22 | Merck Sharp & Dohme Corp. | 5-substituted iminothiazines and their mono- and dioxides as BACE inhibitors, compositions, and their use |
| JPWO2012147762A1 (ja) | 2011-04-26 | 2014-07-28 | 塩野義製薬株式会社 | ピリジン誘導体およびそれを含有するｂａｃｅ１阻害剤 |
| US8883779B2 (en) | 2011-04-26 | 2014-11-11 | Shinogi & Co., Ltd. | Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them |
| US8785436B2 (en) | 2011-05-16 | 2014-07-22 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors |
| WO2012162334A1 (en) | 2011-05-24 | 2012-11-29 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| US8604024B2 (en) | 2011-05-24 | 2013-12-10 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| US9079919B2 (en) | 2011-05-27 | 2015-07-14 | Hoffmann-La Roche Inc. | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors |
| JP2012250933A (ja) | 2011-06-03 | 2012-12-20 | Shionogi & Co Ltd | オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物 |
| KR20140041687A (ko) | 2011-06-07 | 2014-04-04 | 에프. 호프만-라 로슈 아게 | Bace1 및/또는 bace2 억제제로서의 할로겐-알킬-1,3-옥사진 |
| BR112013031510A2 (pt) | 2011-06-07 | 2016-12-27 | Hoffmann La Roche | [1,3]oxazinas |
| US8927535B2 (en) | 2011-07-06 | 2015-01-06 | Hoffman-La Roche Inc. | Cyclopropyl-fused-1,3-thiazepines as BACE1 and/or BACE2 inhibitors |
| AU2012298983A1 (en) | 2011-08-22 | 2014-02-27 | Merck Sharp & Dohme Corp. | 2-spiro-substituted iminothiazines and their mono-and dioxides as BACE inhibitors, compositions and their use |
| UY34278A (es) * | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
| EP2751116B1 (en) | 2011-08-31 | 2016-10-12 | Pfizer Inc | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds |
| US20130073953A1 (en) | 2011-09-21 | 2013-03-21 | Timothy Onyenobi | News headline screenshot viewing system |
| KR20140084146A (ko) | 2011-10-13 | 2014-07-04 | 노파르티스 아게 | 신규 옥사진 유도체 및 질환의 치료에서의 그의 용도 |
| WO2013061962A1 (ja) | 2011-10-24 | 2013-05-02 | 武田薬品工業株式会社 | 二環性化合物 |
| SG11201403956VA (en) * | 2012-01-26 | 2014-10-30 | Hoffmann La Roche | Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines |
| US9493485B2 (en) * | 2012-03-20 | 2016-11-15 | Imago Pharmaceuticals, Inc. | Spirocyclic dihydro-thiazine and dihydro-oxazine BACE inhibitors, and compositions and uses thereof |
| WO2013164730A1 (en) | 2012-05-04 | 2013-11-07 | Pfizer Inc. | Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2. |
| WO2013182638A1 (en) | 2012-06-08 | 2013-12-12 | H. Lundbeck A/S | 2 -aminothiazinylheteroaryls as bace1 inhibitors for the treatment alzheimer's disease |
| MX2014014937A (es) | 2012-06-26 | 2015-03-09 | Hoffmann La Roche | Difluoro-hexahidro-ciclopentaoxazinilos y difluoro-hexahidro-benzo oxazinilos como inhibidores de beta-secretasa 1 (bace1). |
| GB201212871D0 (en) | 2012-07-20 | 2012-09-05 | Eisai Ltd | Novel compounds |
| CA2882389A1 (en) | 2012-09-20 | 2014-03-27 | Pfizer Inc. | Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US9422277B2 (en) | 2012-10-17 | 2016-08-23 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use |
| WO2014062553A1 (en) | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| EP2912035A4 (en) | 2012-10-24 | 2016-06-15 | Shionogi & Co | DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY |
| CN104755484B (zh) | 2012-10-26 | 2016-02-17 | 伊莱利利公司 | Bace抑制剂 |
| EP2931284B1 (en) | 2012-12-14 | 2017-08-23 | Merck Sharp & Dohme Corp. | Bace inhibitors of iminothiadiazine dioxides |
| EP2935282A1 (en) | 2012-12-19 | 2015-10-28 | Pfizer Inc. | CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS |
| EP2935256B1 (en) | 2012-12-19 | 2018-01-24 | Bristol-Myers Squibb Company | 4,6-diarylaminothiazines as bace1 inhibitors and their use for the reduction of beta-amyloid production |
| CN104870000A (zh) | 2012-12-20 | 2015-08-26 | 默沙东公司 | 作为bace抑制剂的c5,c6氧杂环稠合的亚胺基噻嗪二氧化物化合物,组合物及其用途 |
| WO2014099788A1 (en) | 2012-12-21 | 2014-06-26 | Merck Sharp & Dohme Corp. | C5-spiro iminothiadiazine dioxides as bace inhibitors |
| KR20150109429A (ko) | 2013-01-22 | 2015-10-01 | 시에나 바이오테크 에스.피.에이. | Bace1 억제제로서의 플루오로-[1,3]옥사진 |
| TW201446758A (zh) | 2013-03-01 | 2014-12-16 | Amgen Inc | 作爲β－分泌酶抑制劑的全氟化５，６－二氫－４Ｈ－１，３－□－２－胺化合物及其用途 |
| HK1217486A1 (zh) | 2013-03-08 | 2017-01-13 | Amgen Inc. | 作爲β-分泌酶抑制剂的全氟化环丙基稠合的1，3-恶嗪-2-胺化合物以及其使用方法 |
| MA38556A1 (fr) | 2013-04-11 | 2017-09-29 | Hoffmann La Roche | Inhibiteurs de bace1 |
| EP2989081A1 (en) | 2013-04-26 | 2016-03-02 | F. Hoffmann-La Roche AG | Synthesis of bace inhibitors |
-
2014
- 2014-02-27 TW TW103106910A patent/TW201446758A/zh unknown
- 2014-02-27 CA CA2902212A patent/CA2902212C/en active Active
- 2014-02-27 WO PCT/US2014/019100 patent/WO2014134341A1/en not_active Ceased
- 2014-02-27 MX MX2015011313A patent/MX366855B/es active IP Right Grant
- 2014-02-27 EP EP14712418.4A patent/EP2961749B1/en active Active
- 2014-02-27 US US14/192,710 patent/US9296734B2/en active Active
- 2014-02-27 JP JP2015560325A patent/JP6389830B2/ja active Active
- 2014-02-27 AU AU2014223334A patent/AU2014223334C1/en active Active
- 2014-03-05 UY UY0001035361A patent/UY35361A/es not_active Application Discontinuation
-
2018
- 2018-06-25 AU AU2018204589A patent/AU2018204589A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016511258A5 (cg-RX-API-DMAC7.html) | ||
| JP7556010B2 (ja) | ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用 | |
| JP2016510758A5 (cg-RX-API-DMAC7.html) | ||
| KR102485100B1 (ko) | 치환된 우레아 유도체 및 이의 약제학적 용도 | |
| CA2876690C (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| CN105294683B (zh) | Cdk类小分子抑制剂的化合物及其用途 | |
| JP2017523223A5 (cg-RX-API-DMAC7.html) | ||
| EP3541813A1 (en) | Heterocyclic amides as kinase inhibitors | |
| CA3085937A1 (en) | Diazaindole compounds | |
| CA2651363A1 (en) | Triazolopyrazine derivatives useful as anti-cancer agents | |
| JP2012527483A (ja) | ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体 | |
| JP2016525135A (ja) | ＢＥＴタンパク質およびポロ様キナーゼの二重阻害薬としての置換されたジヒドロピリド［３，４−ｂ］ピラジノン類 | |
| CA2682665A1 (en) | Triazinone and diazinone derivatives useful as hsp90 inhibitors | |
| CA2957544C (en) | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use | |
| JP2017537110A (ja) | ヘテロ環式誘導体およびその使用 | |
| JP2010523522A5 (cg-RX-API-DMAC7.html) | ||
| WO2019224773A1 (en) | Heterocyclic amides as rip1 kinase inhibitors | |
| CN105732637B (zh) | 杂芳化合物及其在药物中的应用 | |
| JP2016503785A5 (cg-RX-API-DMAC7.html) | ||
| WO2020012357A1 (en) | Heterocyclic compounds and methods of use | |
| JP7628089B2 (ja) | 三環式化合物およびそれらの用途 | |
| JP2013533868A (ja) | タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用 | |
| JP2020526549A5 (cg-RX-API-DMAC7.html) | ||
| JP2016540803A5 (cg-RX-API-DMAC7.html) | ||
| JP2017513887A5 (cg-RX-API-DMAC7.html) |